Latest Breaking News On - Arkin bio capital - Page 1 : vimarsana.com

HI-Bio Announces Positive Results From Phase 2 Study Of Felzartamab For Late Antibody-Mediated Rejection In Kidney Transplant Recipients

82% (n=9/11) of patients on felzartamab experienced resolution of antibody-mediated rejection per Banff criteria on biopsy at 24 weeks versus 20% (n

United statesHong kongGeorg boUptal patelKatharina mayerUnited network for organ sharingHuman immunology biosciences incUniversity of viennaDivision of nephrologyEuropean renal associationUniversity viennaNew england journalImmunology biosciencesBanff classificationUnited networkOrgan sharing

HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients

HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongCaroline fryMorgan warnersUptal patelKatharina mayerHuman immunology biosciences incUnited network for organ sharingUniversity of viennaUniversity viennaDivision of nephrologyEuropean renal associationNew england journalImmunology biosciencesBanff classificationAssociate professor

HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at 61st European Renal Association (ERA) Congress

HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at 61st European Renal Association (ERA) Congress
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongUptal patelMorgan warnersCaroline fryClinical researchEuropean renal associationAachen universityHuman immunology biosciences incImmunology biosciencesStudy investigatorChief medical officerMonograph capitalAlpha wave globalArkin bio capitalJeito capital

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational.

Hong kongUnited statesOlmsted countyUnited kingdomChuck trianoJack coxTravis murdochPriya singhalMorgan warnersExchange commissionHead of development at biogenGoodwin procterBofa securities incDrug administrationCovington burlingHuman immunology biosciences inc

Biogen Inc : Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational

United statesHong kongOlmsted countyUnited kingdomTravis murdochMorgan warnersPriya singhalChuck trianoJack coxGoodwin procterHead of development at biogenEuropean renal associationA single centerClinical researchCovington burlingExchange commission